[{"id":"39901d4d-3dee-40b7-99f7-2afa8c1da147","acronym":"","url":"https://clinicaltrials.gov/study/NCT01884285","created_at":"2021-01-18T08:27:26.840Z","updated_at":"2024-07-02T16:36:44.639Z","phase":"Phase 1","brief_title":"AZD8186 First Time In Patient Ascending Dose Study","source_id_and_acronym":"NCT01884285","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER • PGR • PTEN • PIK3CB","pipe":" | ","alterations":" HER-2 negative • PIK3CB mutation","tags":["HER-2 • ER • PGR • PTEN • PIK3CB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CB mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • AZD8186 • vistusertib (AZD2014)"],"overall_status":"Completed","enrollment":" Enrollment 147","initiation":"Initiation: 07/09/2013","start_date":" 07/09/2013","primary_txt":" Primary completion: 03/31/2019","primary_completion_date":" 03/31/2019","study_txt":" Completion: 02/07/2020","study_completion_date":" 02/07/2020","last_update_posted":"2020-05-29"}]